ImmuPharma plc

Equities

IMM

GB0033711010

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 09:05:18 17/05/2024 pm IST			5-day change	1st Jan Change
2.405 ^GBX	+6.89%		+11.09%	+44.27%

29/04	Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director	CI
02/04	Immupharma jumps amid new IP strategy for P140 technology platform	AN

ImmuPharma "absolutely delighted" to push on with new clinical trial

June 28, 2023 at 05:09 pm IST

(via NewsDirect)

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy visited Thomas Warner at the Proactive London studio after confirming to the market that the specialty biopharmaceutical will be moving forward into a key phase 2/3 adaptive clinical trial, alongside its US partners Avion Pharmaceuticals. McCarthy says that he's "absolutely delighted" to be moving forward with the study and emphasises the significant potential of its deal with Avion, including milestone payments of up to $70 million and double-digit royalty percentages, in addition to obvious benefit to patients. McCarthy also mentions ongoing discussions for more commercial partnerships and the potential for major breakthroughs in the future.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Latest news about ImmuPharma plc

Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director	29/04	CI
Immupharma jumps amid new IP strategy for P140 technology platform	02/04	AN
ImmuPharma plc Initiates New Intellectual Property Strategy to Significantly Enhance the Patent Life and Commercial Value for Its P140 Technology Platform	02/04	CI
Incanthera says first order from skincare deal doubles	25/03	AN
Stocks make tepid start to new week	25/03	AN
AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss	25/03	AN
EARNINGS AND TRADING: Challenger signs farm-out; Ricardo revenue up	06/03	AN
EARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrows	19/12	AN
Immupharma Decides to Move Directly to Late-stage Trial of Lupus Therapy	19/12	MT
ImmuPharma Appoints Contract Research Organization for Late-stage Lupuzor Trial	19/12	MT
Immupharma plc Announces Key Updates on Its Late Stage P140 Program, in Patients with Systemic Lupuzortm	19/12	CI
Incanthera signs skincare stocking deal, raises GBP1 million	18/12	AN
ImmuPharma plc Announces Executive Appointments	09/11	CI
Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development	07/11	CI
RA International loss narrows as revenue grows	07/23/07	AN
British Biopharmaceutical Company ImmuPharma Closes Retail Offer of New Shares	07/23/07	MT
FTSE 100 Ends Negative Month on Subdued Note	31/23/31	DJ
ImmuPharma Targets GBP2 Million Equity Raise; Stock Sinks 12%	31/23/31	MT
ImmuPharma launches GBP2 million fund raise as interim loss narrows	31/23/31	AN
Earnings Flash (IMM.L) IMMUPHARMA Reports H1 Revenue GBP69,959	31/23/31	MT
Earnings Flash (IMM.L) IMMUPHARMA Posts H1 Loss GBX-0.25	31/23/31	MT
ImmuPharma plc Reports Earnings Results for the Half Year Ended June 30, 2023	31/23/31	CI
ImmuPharma agrees 12 month extension to Incanthera warrant instrument	21/23/21	AN
ImmuPharma Secures 12-month Extension to Incanthera Warrant Instrument	21/23/21	MT
ImmuPharma Initiates Talks with Potential Partners for Licensing Deals	11/23/11	MT

Chart ImmuPharma plc

Duration

Period

More charts

Company Profile

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company is focused on developing peptide bio-drugs in specialty therapeutic areas. Its portfolio includes peptide therapeutics for autoimmune diseases and anti-infectives. Its lead program, P140 (Lupuzor), is an autophagy immunomodulator for the treatment of lupus. Its pipeline is focused on two therapeutic areas: autoimmunity/inflammation and anti-infectives. Its pipeline products in autoimmunity and inflammation therapeutic area includes Lupuzor and P140 for CIDP. Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB, a peptide-based drug that offers a potential improvement on the limiting side effects and poor administration regime of Amphotericin-B (AMB) formulations. BioCin, a peptide-based drug based on an existing antibacterial used in high medical need and in many cases as the last line of defense.

Sector

Biotechnology & Medical Research

Calendar

23/05/2024 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IMMUPHARMA PLC	+44.27%	1.27Cr
MODERNA, INC.	+33.63%	5.09TCr
IQVIA HOLDINGS INC.	-0.09%	4.21TCr
LONZA GROUP AG	+49.62%	4.2TCr
CELLTRION, INC.	-4.96%	2.92TCr
ICON PUBLIC LIMITED COMPANY	+11.18%	2.6TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	1.89TCr
BIO-TECHNE CORPORATION	+8.61%	1.32TCr
UNITED THERAPEUTICS CORPORATION	+24.73%	1.22TCr
MEDPACE HOLDINGS, INC.	+28.31%	1.22TCr

Other Biotechnology & Medical Research